4//SEC Filing
Harris Erik 4
Accession 0001209191-23-016039
CIK 0001515673other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 7:51 PM ET
Size
11.2 KB
Accession
0001209191-23-016039
Insider Transaction Report
Form 4
Harris Erik
EVP & Chief Commercial Officer
Transactions
- Award
Common Stock
2023-03-01+2,663→ 38,823 total - Award
Common Stock
2023-03-01+22,000→ 60,823 total - Sale
Common Stock
2023-03-01$45.25/sh−3,664$165,796→ 57,344 total - Award
Stock Option (Right to Buy)
2023-03-01+39,400→ 39,400 totalExercise: $45.65Exp: 2033-03-01→ Common Stock (39,400 underlying)
Footnotes (6)
- [F1]Represents shares of common stock which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric.
- [F2]Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
- [F3]Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- [F4]Includes 185 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2022
- [F5]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F6]On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Documents
Issuer
Ultragenyx Pharmaceutical Inc.
CIK 0001515673
Entity typeother
Related Parties
1- filerCIK 0001780113
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 7:51 PM ET
- Size
- 11.2 KB